Oticara Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
5
- Latest Deal Type
-
2ndary - Private
- Investors
-
5
Oticara General Information
Description
Developer of a biopharmaceutical therapy designed to treat chronic rhinosinusitis through targeted intranasal delivery. The company's therapy offers physician-administered localized corticosteroid delivery, semisolid formulation for sustained mucosal contact, and single-dose application with reduced systemic exposure, enabling physicians to treat patients with persistent sinus conditions and improve symptom control through targeted care.
Contact Information
Website
www.oticara.comCorporate Office
- 12319 North Mopac Expressway
- Suite 300
- Austin, TX 78758
- United States
Corporate Office
- 12319 North Mopac Expressway
- Suite 300
- Austin, TX 78758
- United States
Oticara Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Secondary Transaction - Private | Completed | Clinical Trials - Phase 2 | ||||
| 1. Seed Round | 15-May-2022 | Completed | Clinical Trials - Phase 2 |
Oticara Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed 2 | ||||||||
| Seed 1 | ||||||||
| Founders | 2,603,466 | $0.000100 | $0.44 | $0.44 | 1x | $0.44 | 0% |
Oticara Patents
Oticara Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2021334325-A1 | Compositions devices and methods for treating nasal, otic and other tissue infection and/or inflammation | Pending | 26-Aug-2020 | ||
| EP-4203958-A1 | Compositions devices and methods for treating nasal, otic and other tissue infection and/or inflammation | Pending | 26-Aug-2020 | ||
| EP-4203958-A4 | Compositions devices and methods for treating nasal, otic and other tissue infection and/or inflammation | Pending | 26-Aug-2020 | ||
| WO-2022047042-A1 | Compositions devices and methods for treating nasal, otic and other tissue infection and/or inflammation | Inactive | 26-Aug-2020 | ||
| CA-3190833-A1 | Compositions, devices and methods for treating nasal, otic and other tissue infection and/or inflammation | Pending | 26-Aug-2020 | A61K9/06 |
Oticara Signals
Oticara Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Healthcare Equity Angels | Angel Group | Minority | ||
| K20 Fund | PE/Buyout | Minority | ||
| Keiretsu Capital | Venture Capital | Minority | ||
| Keiretsu Forum | Angel Group | Minority | ||
| Springbok Ventures | Venture Capital | Minority |
Oticara FAQs
-
When was Oticara founded?
Oticara was founded in 2017.
-
Where is Oticara headquartered?
Oticara is headquartered in Austin, TX.
-
What is the size of Oticara?
Oticara has 5 total employees.
-
What industry is Oticara in?
Oticara’s primary industry is Drug Discovery.
-
Is Oticara a private or public company?
Oticara is a Private company.
-
What is Oticara’s current revenue?
The current revenue for Oticara is .
-
How much funding has Oticara raised over time?
Oticara has raised $5.9M.
-
Who are Oticara’s investors?
Healthcare Equity Angels, K20 Fund, Keiretsu Capital, Keiretsu Forum, and Springbok Ventures have invested in Oticara.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process